Study 1 consisted of a pilot safety phase ( N = 8 ) during which subjects received a single body-weight-adjusted subcutaneous dose of lipegfilgrastim 25 g/kg and a dose escalation phase ( N = 45 ) wherein subjects received lipegfilgrastim 50 or 100 g/kg or pegfilgrastim 100 g/kg .